Skip to content
DataLookout
Menu

NCT05551273

Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV

StatusTerminated
PhasePhase 2
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 34 versions: 33 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Reclassified as terminated (was completed) Sponsor's reason: ACTG Network funding disruptions Show 8 more changesShow less
    • Results posted: Nov 17, 2026
    • Eligibility criteria shortened, about 37 words
    • Primary endpoints revised (3)
    • Start date: May 5, 2023 to May 1, 2023
    • Secondary endpoints revised (10)
    • Study description expanded, about 48 words
    • Study sites revised (12)
    • Collaborators expanded, about 2 words
  2. Minor Study sites: 26 to 12v33
  3. Minor Trial completed
    • Study completion date changed from estimate of Apr 29, 2026 to Apr 8, 2026
    v32
  4. Minor Study sites: 27 to 26v30
  5. Minor Study sites: 29 to 27
    • Primary completion date changed from estimate of Nov 15, 2025 to Oct 29, 2025
    v29
Show 27 earlier versionsHide 27 earlier versions
  1. Minor Study sites: 30 to 29v28
  2. Minor Study sites: 31 to 30v27
  3. Minor Study sites: 32 to 31v26
  4. Minor Study sites: 36 to 32v25
  5. Minor Study sites: 37 to 36v24
  6. Minor Study sites: 39 to 37v23
  7. Notable Primary completion date: Nov 19, 2026 to Nov 15, 2025
    • Study completion date: May 15, 2027 to Apr 29, 2026
    v22
  8. Notable Trial status: Suspended to Active, Not Recruiting
    • Enrollment target: estimated 48 to confirmed 29
    v21
  9. Stopped Trial status: Recruiting to Suspended Sponsor's reason: Temporarily Closed (Paused) to Accrual
    • Site details revised at 39 of 39 sites
    v20
  10. Minor Site details revised at 1 of 39 sitesv19
  11. Minor Site details revised at 1 of 39 sitesv18
  12. Minor Site details revised at 1 of 39 sitesv17
  13. Minor Study sites revised (39)v16
  14. Notable Primary completion date: Jan 19, 2025 to Nov 19, 2026
    • Study completion date: Jul 17, 2025 to May 15, 2027
    v15
  15. Minor Study sites revised (39)v14
  16. Minor Study sites: 38 to 39v13
  17. Minor Site contacts updated at 1 of 38 sitesv12
  18. Notable Primary completion date: Mar 12, 2024 to Jan 19, 2025
    • Study completion date: Nov 2, 2024 to Jul 17, 2025
    v11
  19. Minor Site details revised at 2 of 38 sitesv10
  20. Minor Start date changed from estimate of Apr 30, 2023 to May 5, 2023v9
  21. Notable Start date: Mar 31, 2023 to Apr 30, 2023
    • Study sites: 37 to 38
    v8
  22. Minor Study sites revised (37)v7
  23. Notable Start date: Dec 14, 2022 to Mar 31, 2023
    • Site contacts updated at 3 of 37 sites
    v6
  24. Minor Study sites: 36 to 37v5
  25. Minor Site details revised at 2 of 36 sitesv4
  26. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 36 of 36 sites
    v3
  27. Minor Start date: Nov 23, 2022 to Dec 14, 2022v2
  1. Study First Submitted
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Proportion of Participants Who Experienced Grade ≥2 Adverse Events (AEs) in Arm A
Timeframe: From study treatment initiation through Week 24
Proportion of Participants Who Prematurely Discontinued Treatment Due to Adverse Events (AEs) in Arm A
Timeframe: From study treatment initiation through Week 24
Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in Quantitative HBsAg (qHBsAg) After SLGN Treatment at Week 24
Timeframe: Week 24

Secondary (10)

Proportion of Participants With ≥1 log10 IU/mL Decline From Baseline in qHBsAg at Any Time During the Study After SLGN Treatment Initiation
Proportion of Participants With ≥0.5 log10 IU/mL Decline From Baseline in qHBsAg After SLGN Treatment at Week 24
Proportion of Participants With ≥0.5 log10 IU/mL Decline in qHBsAg From Baseline at Any Time During the Study After SLGN Treatment Initiation
Proportion of Participants Who Achieve HBsAg Loss After SLGN Initiation and Who Sustain HBsAg Loss During Follow-up
Changes From Baseline in qHBsAg Levels
Show 5 moreShow less
Proportion of Hepatitis B E-antigen (HBeAg) Positive Participants at Baseline Who Lose HBeAg at Any Time During the Study
Proportion of Hepatitis B E-antibody (Anti-HBe) Negative Participants at Baseline Who Develop Anti-HBe at Any Time During the Study
Proportion of Hepatitis B Surface Antibody (Anti-HBs) Negative Participants at Baseline Who Develop Anti-HBs at Any Time During the Study
Number of Participants With Plasma HIV RNA >50 Copies/mL
Number of Participants With Serum HBV DNA >50 IU/mL

Arms and interventions

Arm AExperimental

Participants received Selgantolimod 3 mg (two 1.5 mg tablets) once weekly for 24 weeks.

Arm BPlacebo comparator

Participants received matching Placebo for Selgantolimod once weekly for 24 weeks.

Drugs: Selgantolimod, Placebo

Sites

12 sites in 4 countries

United States 7, Brazil 2, Thailand 2, Peru 1